Etid klinik pou Lupus nan Oklahoma
7 etid pou Lupus ap chèche patisipan nan sit nan Oklahoma.
Vil nan Oklahoma
Tèks ofisyèl etid la (Anglè)
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
- Research Site, Oklahoma City
- Research Site, Oklahoma City
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 25, 2026 · NCT07430306A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
- Oklahoma Medical Research Foundation, Oklahoma City
Ap rekriteFaz 2
Laj 18 a 74 · Tout sèks · Mizajou Sep 17, 2026 · NCT07409181A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
- Oklahoma Medical Research Foundation, Oklahoma City
Ap rekriteFaz 4
Laj 18 a 75 · Tout sèks · Mizajou Sep 9, 2026 · NCT06875960A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
- Oklahoma Medical Research Foundation, Oklahoma City
Ap rekriteEtid obsèvasyon
Laj 16 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT07175285Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease
- Oklahoma Medical Research Foundation, Oklahoma City
Ap rekriteFaz 3
Laj 55 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT05799378A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- University of Oklahoma, Oklahoma City
Ap rekriteFaz 1
Laj 12 a 70 · Tout sèks · Mizajou May 22, 2026 · NCT06308978Safety of the Herpes Zoster Subunit Vaccine in Lupus
- Oklahoma Medical Research Foundation, Oklahoma City
Ap rekriteFaz 4
Laj 18 a 90 · Tout sèks · Mizajou Dec 26, 2025 · NCT05559671Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.